Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
about
Fatty acids derived from royal jelly are modulators of estrogen receptor functionsDry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agentA strategy in the design of micellar shape for cancer therapy.Improved intervention of atherosclerosis and cardiac hypertrophy through biodegradable polymer-encapsulated delivery of glycosphingolipid inhibitor.Nanomedicine for uterine leiomyoma therapyBiodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier.Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivoHydrogels for controlled pulmonary delivery.Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery.Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.Dry powder inhalation: past, present and future.Soft particle analysis of electrokinetics of biological cells and their model systems.Microencapsulation of alpha-mangostin into PLGA microspheres and optimization using response surface methodology intended for pulmonary delivery.Poly(glycerol adipate-co-ω-pentadecalactone) spray-dried microparticles as sustained release carriers for pulmonary delivery.Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration.Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution.Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles.Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance.Evaluation of PEG and mPEG-co-(PGA-co-PDL) microparticles loaded with sodium diclofenac.Caveolae-mediated endocytosis of intratracheally instilled gold colloid nanoparticles at the air-blood barrier in mice.Paclitaxel and quercetin nanoparticles co-loaded in microspheres to prolong retention time for pulmonary drug delivery.In vitro evaluation of polyethylene glycol based microparticles containing azithromycin.Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability.Biodegradable polymeric nanocarriers for pulmonary drug deliveryInhalable, bioresponsive microparticles for targeted drug delivery in the lungsEvaluating the Controlled Release Properties of Inhaled Nanoparticles Using Isolated, Perfused, and Ventilated Lung Models
P2860
Q28744012-2F735BE5-05E0-4AF8-B3A3-092EFAEA5ECDQ33811796-44B65BF9-CAAE-4CB1-A19B-B7C063CF5BFEQ34489400-6165C667-2CB2-42E0-BB95-6D1492DB5FFAQ36020532-0F0E42C4-1DA9-4C9C-B034-0C6C5988F79DQ37124426-E323A24C-2C2C-4AA6-9635-6B9E9AB7439EQ37429043-0AAF118D-8749-4903-999F-230F49C4F93BQ37442003-AF0E5D07-C2A3-44A5-A24B-A3AF27FA5AFDQ38151737-648D4B5C-9970-4335-B21D-6FFDBF3B6EC3Q38714479-CDA7497F-D456-42EC-B42C-3905876B8EC9Q38789348-3A17A2E3-242A-4C4C-9C47-B160FADAFA32Q38830375-9AC0C04F-49B9-42F5-BD74-6D3365F5C2EDQ39017353-41BED39A-F6D1-40A1-8417-E315234D29FBQ39158268-F4922046-CFA4-4124-AA10-7B7E0D144591Q39550161-A843C02A-ABF8-429F-AE8D-64F4EF1A8937Q39856908-AA8556C0-F8DA-45B8-8488-B333C0FBE735Q39897715-9302562C-8FAA-4340-83A4-CDD52971224EQ40268859-A033AE62-53C9-4A80-87D5-1746A7B137CDQ41989593-56515357-5015-4DBF-AAF0-49894E14E881Q42150353-10E3901D-0CE0-4FF6-B2E3-40C088967BC2Q45875340-EC4FDAF4-F790-468B-807B-0FCC1AFC7793Q47108280-BA517594-D6D8-483D-97C2-8B3479210A4BQ50449781-BA904E80-1DB0-4114-BE01-B6085D725059Q51085961-83D2DFA6-EAB9-402B-AB35-8E7F2AB821F5Q57381746-4E499678-8072-4E32-9A67-D1386B56A49CQ58062004-25FE5239-30E5-467E-981D-28A943C9D0EDQ58691546-AE5C716A-674B-43A3-83BC-8BA110446937
P2860
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
@ast
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
@en
type
label
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
@ast
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
@en
prefLabel
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
@ast
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
@en
P1476
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
@en
P2093
Jennifer Fiegel
P304
P356
10.1016/J.JCONREL.2004.02.018
P407
P50
P577
2004-05-01T00:00:00Z